C-OBIETrivium Vet
veterinary therapeutics, mTOR inhibition, sirolimus
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-OBIE
C-OBIEC-OBIEveterinary therapeutics, mTOR inhibition, sirolimus
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Products | TriviumVet <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact Us Products Feline Chronic Kidney Disease (CK … ida College of Veterinary Medicine. The FDA have granted TriviumVet approval to apply for expanded conditional approval for this product and our team are working towards making a regulatory submission to the FDA in early 2024. Where Can I Get This Product? TRIV307 is proposed for use in cats diagnosed with chronic kidney disease (CKD) and is undergoing review by global regulatory authorities. Further details will be coming soon, and you can follow our social platforms @triviu
TriviumVet - Innovative Animal Health Therapeutic Solutions <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact Us Game
felycin®-CA1 <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact Us Register your interest to become a prescriber below
Global Animal Health Partnering Terms and Agreements | Current Partnering The store will not work correctly when cookies are disabled. JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser. My Account My Wish List Sign In Compare Products Create an Account Skip to Content Toggle Nav My Cart Search Search Search Menu Home CP Reports Store Industry sector reports Deal type reports Stage partnered reports Technology reports Therapy reports Subscription services Market forecast reports Current Agreements CP Knowledge Cen … harmaceutical, Curio Genomics, CVM Ecografía, Daiichi Sankyo, Danish Innovation Fund, Dawn Health, Dechra Pharmaceuticals, Deinove, Delf, Department of Defense, Destination Pet, Diversigen, Domes Pharma, Dovetail Genomics, Dragonfly Therapeutics, DSM, DW Healthcare, Dyadic International, EBOS Group, Eko Health, Elanco, ELIAS Animal Health, Emergent BioSolutions, Emollivet, Energesis Pharmaceuticals, Enveric Biosciences, Envigo, EPiQ Animal Health, epitoMAP, Epivax, eQcell, EQ … lity, risk, and control are allocated within agreements Designed for real-world application Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including: Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour Advisory, legal, and consult … ogy 2016-2026 $3,995.00 Add to Wish List Add to Compare Gene Editing Markets by Application, Technology, Place, Industry and Product with Executive and Consultant Guides 2025 to 2029 $6,995.00 Add to Wish List Add to Compare Licensing Deals in Pharmaceuticals 2020-2026 $4,995.00 Add to Wish List Add to Compare We found other products you might like! Gene Editing Markets by Application, Technology, Place, Industry and Product with Executive and Consultant Guides 2025 to 2029 $
TriviumVet Receives FDA Conditional Approval for Liavium-CA1 | TriviumVet LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreeme … ps://bit.ly/4absEby #JAGX Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs | Jaguar Health, Inc. jaguarhealth.gcs-web.com 5 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Jaguar Health 4,836 followers 4d Report this post Jaguar Completes Submission of NADA for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diar … ps://bit.ly/4absEby #JAGX Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs | Jaguar Health, Inc. jaguarhealth.gcs-web.com 7 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Dr. Harshit Gupta 2w Report this post "Is this dose right for a 3.2 kg cat with Stage 2 CKD?" Every vet has asked themselves this question at 8 PM on a Saturday. Do … an oral treatment for atopic dermatitis in companion dogs, and has submitted an application for marketing approval. HK inno.N completes phase 3 trial of Korea's 1st JAK-1 inhibitor for canine atopic dermatitis koreabiomed.com Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Sharon Teitelman 1w Report this post One of the latest and most concerning of these substances is medetomidine, a powerful veterinary sedative now being detected in fentanyl sa
LANTERN PHARMA INC., 10-K filed on 3/30/2026 Annual Report Cover Financial Statements Notes to Financial Statements Accounting Policies Notes Tables Notes Details Series Schedules Risk Return Reports Other Uncategorized Cover Consolidated Balance Sheets Consolidated Balance Sheets (Parenthetical) Consolidated Statements of Operations Consolidated Statements of Comprehensive Loss Consolidated Statements of Stockholders' Equity Consolidated Statements of Stockholders' Equity (Parenthetical) Consolidated Statements of Cash Flows Pay vs Performance Disclosure Insider Trading Arrangements Cybersecu … eding 12 months (or for such shorter period that the registrant was required to submit such files). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition The par value per share of security quoted in same currency as Trading currency. Example: '0 … .   The Company plans to pursue periodic capital raises and also plans to apply for grant funding in the future to assist in supporting its capital needs. In July 2025, the Company entered into an ATM Sales Agreement (“ATM”), with ThinkEquity LLC (“ThinkEquity”), as sales agent, pursuant to which the Company may offer and sell up to $ 15,530,000 of its common stock from time to time, in “at-the-market” offerings to or through its sale … d marketable securities on hand as of the date of this report will enable us to fund our operating expenses and capital expenditure requirements until at least approximately late July 2026 to mid September 2026. We will need substantial additional funding in the near future, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our drug development programs or commercialization efforts.   The Company’s ability to contin … ck Compensation . Under ASC 718, awards are valued at fair value on the date of grant, and that fair value is recognized over the requisite service period. Forfeitures are accounted for as they occur.   Recently Adopted Accounting Pronouncement   In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures , whi
Pregabalin - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 11 Jun 2026 Pregabalin Last update 11 Jun 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Summary Pregabalin, commonly referred to as Lyrica®, is a well-known anticonvulsant medication, which has found its footing in the treatment of various medical conditions. Such conditions include but are not limited to anxiety disorders, epilepsy, and neuralgia. The mechanism of action tha … ation for submission to the FDA under its active Investigational New Drug (IND) application. About Ketamir-2 Ketamir-2 is a proprietary, orally bioavailable investigational new molecular entity designed to selectively modulate the NMDA receptor (PCP binding site) with low binding affinity and limited off-target receptor activity. In validated preclinical models of neuropathic pain, including paclitaxel-induced neuropathy and sciatic nerve ligation, Ketamir-2 demonstrated impr … nditionally approved by FDA pending a full demonstration of effectiveness under application number 141-606. Liavium-CA1 is a Schedule V controlled substance and should be handled and stored according to federal and state controlled-substance requirements. Based on publications in the scientific literature, the following adverse reactions are associated with administration of pregabalin in dogs: somnolence, increased appetite, decreased activity, increased water intake, decrea
TriviumVet Blog - €5million raised in funding to invest in exciting animal drug pipeline <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Up
%PDF-1.3 %��������� 4 0 obj > stream x����l9n���*���YkU��Hrd� 9pv����s��������?6�q��n��(�")j�_�����������8�����|���O�8����q=����&����_i~����?.����ӷ�A�p�>����uο=h�m���-��癞����������=���}��sN%��s�����cۏ�)�|>�����z�/��/g����~Ą����uy�[櫸_����ƴ���+�1����N����{���``%A��Ϗ�rG ��/�Sw����/Z���� ��Z~l�����b]>���������M�TV^������ ���p����2 Dž�ޟ���s���7T�`J��M�?Ϸ���z���M���? ��ȶ���_ϯ�����-�����o��x���|��3� J>� ���� ъE� �&�r��T��k�s������rݟ�~z�!�#�;�~=1z��`� EJ�Q��+��l��P�8�2���#nN��� �� ��=�4����Ӿ���Ȝݮ�l��������З����0���������������> 7���`��KMr�m~I���Cۛ0&�� /4��pK Xj��nB���� … 6� \��v��όv���,�W�ĩ����W��6�����oc^�}G�� �� ��� З�g�� ��յo�Z����]�g=9�:rFP���x�� �Ek3�� ��m�p��y����,� p\�E}9� &�$���ʧ�"�kٺ���g��_k�W��G������=?�SO��j�.��X�#ँ�:W�M�k~��#��~��gĝ3b��c��:�;��گ�V����S�۵u�ԕl+��}�µ 4����W_#� �G�=Oj{h�P��A��{W�W/ֺ�)I����}.�[a"� ����c�mZ�=G[E\a�%*?E�}� fT�J��ZkO3 ��J�j )�����Ϧ �.��U�0��\^�h�#��/��,-e�:� ^:��IJB~��V.5>����w>^�Μ 4�8�Id�֡�����z��\[:��|��3 � ��ֻ�iz�Şcߦ�gM�� m8��G�3�|E��{�.{�ݺ�R}F[ J��|$��V … 5�o�g�9�!�9i n���}��`|��yq;��� }(y�Y5ʿ8�i�:�|�mY~�5�u/j�> �-����%x��d+$RFp��FU�G�7�ӝ� ��8���Ak��C|mo� �D�5����a�K� # ��q9 sҾYoxW�~��:-؆hWkB� �R=�C^�9�E9+3��Fn4�̻��5X5�D���m��������Ww�o�~!�� b��.v$&2q�T��EyY�#��RRZF;�>�x�k�W��i�Z���F�l�w��v�?�M{9F �%5��q�eM'���ºL:��kkq��}�2�`2T�Pw/~ބ����]_�W�h��z�NJƭƄ�N |(�w >ۂ�ΥJ-�-�������\X�!��z������$֍ +� �O� =rFl""!�{���~ſ�|h��> ~�_K�#N�!�|E�8Ss�*B� d ���F}�_ď����ŗ7 �����z�u���9�_�h��z … M��� ƽ��!e��(�e���=��sE�t^��ܯ9j��%��4�֖�}�8ۭ���tS�=� � ���Ե�'�CB�Iz���@�ܥrFp;W� b� &6�N���Y;wKOS����Β�c�]oKk'۫4w�L�q��I,e@]����8�yu�����m� ��k��BT���)�Wl� 䟨��ǿ�4h���4]j�P�q�y�5B2C�e�� �f�k�~ռ?�G� F��?(����dd�K�x�| \4�'�=?�3zn/K�w6 5��q�o9���h��>�J���' e�*���g5�^0����N� 4� ��u��G��m�0����^��Gy�~0� �WM���B���h�Pc��&3�~ld��vg���w¾!� �Y��s�1��H��g�_"�>*�V���=M�3�+�U^I$� ��Z��>x�@�|E��z "��,�1�1����^��b}GS��}%m�8�AF �GV��0x8�|�y ��8�[� �� … ��T��� 1�5��qO��|u'V�).�%�w��?1� (c��S �R+�VI��Ѯ�����Μe���'ğ٧�>#�Tڦ�]@�K`�rFp{��xI��� ���>�vku't q�Y~' R����)5u�����~k� e�-��R��Kv�������ol|�� ��?����K��hJz+|W���� ��68�8T�խ�g�N��y&�� u�Ƴ �*瑌�=z�c0���ɩ����� ʙdž2���eU.ܯF�5�P?����&� dc���X�JQ�{��~���(���Y4�wӳ����� 9��IT>�H�_�ѣ:�J�����q *�N���F����������0 )99�>���G��RRm;o��
%PDF-1.4 %���� 1 0 obj > endobj 7 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj > endobj 6 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 18 0 obj > endobj 19 0 obj > endobj 20 0 obj > endobj 21 0 obj > endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj > endobj 25 0 obj > endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > endobj 29 0 obj > endobj 30 0 obj > endobj 31 0 obj > endobj 32 0 obj > endobj 33 0 obj > endobj … D��iS�a�?��e�B�%��5�����e� y� `k����~��*| _��4�*��'�6�`WP+A�cO��]�x@�rFp H�x�J�B���� ��jIk����oD-!.��Z@����Fp�e���P1u��[��b . )T�'p�U�?��;����G�� $)+�{c��X��C�Ń��ϒ���N(��~��%�9��>�X�eS' �g����R,^&����h��������xQ�C`�ж�+�^���_7(� 8l�����ʶi� ��� �y�;y날wCkp�}�����F,ΦA�v�ࡣ�f��Αix�X�":B��P�׀b��ϼ'��[�v�s������-����7� ��Jf^��(���*�K� -��}sz���Z3�.~ռ�ϼ,�e�^!W��0w��2�t�U� 2��՝�L!�AAW� ���p\J�l���%wg���9��N* ��ڤ�,߱/b�� … �)7�.�"�n���W�.�n�1g?�����5=:_�KL��e, �_��'���x�=2�g��>� � ��7Ⳁ0 ��#��y!�rFp������1 ���`l�����r *9��9��/�(�ɭɪ�x'ž!��kA�Z����~ �e�|g����|7��S�� ��-a�-W��_ x�? [˨���k���gL��C ޙk�x�����|%����R��� �?���&� ��?�6��Ğ"�^� ^jZ���� |;��]��>�Mys�\�v�$�M8щh��;�0 -�ᯋ�Z����� ���4-?��,�7�t�����W����Z ��]]Ѵ�_�D����7����U��g߄�%����~|Vӥ���鶞 O k?������_� ������ /x#���Ɩ���V�V���K���O���-h�����������5Z�� �(����2{ x�Ƒ��C� ,kw�|F }\�o�I.��Z�?�i
EX-10.11 19 ea120601fs1ex10-11_lantern.htm ASSIGNMENT AGREEMENTDATED AS OF JANUARY 5, 2018 WITH BIONUMERIK PHARMACEUTICALS, INC Exhibit 10.11 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CONFIDENTIAL ASSIGNMENT AGREEMENT THIS ASSIGNMENT AGREEMENT (the “Agreement”) is made and entered into, as of the Effective Date, by and between Lantern Pharma, Inc. (hereinafter referred to as “Lantern”) a … xist in such country, fifteen (15) years after May 31, 2016. (3) “ Application for Marketing Approval ” means any act of submission of materials, information, data, documents, etc. to a Regulatory Authority required to obtain a Marketing Approval for the Product in the Territory, such as NDA in the US and MAA in the EU. “Initial Application for Marketing Approval” means the initial application submitted to a Regulatory Authority to obtain a Mark … patent, information or other intellectual property rights, and has the right to grant the other Party a license (or sublicense) or other rights on the terms and conditions set forth herein. (9) “ Development ” means clinical and non-clinical studies in the Field in the Territory, and any other developmental activities in the Territory required to obtain Marketing Approvals of the Product in the Field in the Territory, and clinical and non-clinical studies r … oved costs for payment of maintenance fees, filing and patent prosecution fees, grant and issue fees, and reasonable fees of patent counsel and patent agents paid or incurred by or on behalf of BioNumerik for the maintenance and advancement of the Patent Rights in the Territory prior to the Closing Date. (24) “ Patent Rights ” means (a) the patents and patent applications listed on Exhibit (1) hereto, as amended from time to time by agreement of the Parties … he foregoing, including foreign equivalents, and (d) any other patent or patent application Controlled by BioNumerik immediately prior to the Closing Date or thereafter by Lantern whose claimed subject matter covers the Compound or Product, processes to make the Compound or Product, uses of the Compound or Product, or methods of administration or
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2 Commitments and Contingencies 9 Months Ended Sep. 30, 2021 Commitments and Contingencies Disclosure [Abstract]   Commitments and Contingencies Note 4. Commitments and Contingencies   General.   The Company has entered into, and expects to enter into from time to time in the future, license agreements, strategic alliance agreements, assignment agreements, research service agreements, and similar agreements related to the advancement of its product candidates and research and development efforts. Significant agreements are described in de … nse Agreement.   As part of the Second Addendum, the Company has agreed to apply for specified orphan drug designations for LP-184 in the US and EU. The Second Addendum also amends and clarifies other provisions of the Technology License Agreement, and provides the Company with the ability to recover a portion of initial payments made under the Second Addendum from sublicense fees or royalty payments that may be made to AFC by the Company or third parties prior to Januar … e milestone payments to AF Chemicals at the time of an Investigational New Drug Application (“IND”) filing relating to LP-184 and also upon reaching additional specified milestones in connection with the development and potential marketing approval of LP-184 in the United States, specified countries in Europe, and other countries.   The AFC License Agreement also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit p … on with existing and future research and service provider agreements.   EU Grant   In September 2018, Lantern Pharma Limited, a wholly owned subsidiary of Lantern Pharma Inc., was awarded a grant by the UK government in the form of state aid under the Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the “General Block Exemption”), Article 25 Aid for research and development projects, state aid notification no. SA.40154. The grant was awarded to … he Company’s research and development activities in Northern Ireland, the grant will reimburse the Company 50% of its research and development expenses not exceeding GBP 24,215 of vouched and approved expenditures within specific categories. The grant contains some reporting and consent requirements. The grant will remain in force for a per
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Waterford's vet R&D company TriviumVet acquired by US group Home Technology Business Enterprise Comms Start-ups All Science Innovation Machines Climate All Careers Advice People Employers Jobs News All AI More AI Policy Advertise Follow Us Contact us About Cookie & Privacy Policy Login TECHNOLOGY BUSINESS ENTERPRISE COMMS START-UPS ALL SCIENCE INNOVATION MACHINES CLIMATE ALL CAREERS ADVICE PEOPLE EMPLOYERS JOBS NEWS ALL AI MORE AI POLICY ADVERTISE FOLLOW US CONTACT ABOUT COOKIE & PRIVACY POLICY Login Subscribe BUSINESS ENTERPRISE COMMS START-UPS ALL BUSINESS Waterford’
TriviumVet - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Co … apeutics for the treatment of dogs health $250M Khosla Ventures , The Longevity Fund & 17 others 58/100 2nd Gallant 2018 , Los Angeles ( United States ) , Series B Provider of stem cell based regenerative therapy for dogs $61.5M Bold Capital Partners , Maveron & 13 others 56/100 3rd Anivive 2015 , Long Beach ( United States ) , Series C Developer of therapeutics for animals $44.3M LEONID , FDA & 1 others 54/100 4th Vétoquinol 1933 , Lure ( France ) , Public Develo
Waterford's vet R&D company TriviumVet acquired by US group | Silicon Republic Knowledge & Events Management Ltd LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo … your comments to the VMD at [email protected] . The VMD will compile and submit all comments to the relevant VICH expert working group for consideration as the VMD is a Standing Member of VICH. There is a template and format for providing such comments. https://lnkd.in/e3A-5BCj . Consultation: target animal safety evaluation for veterinary monoclonal antibody products gov.uk Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in TOPRA - The Organ
TriviumVet Blog - A great catch up with our colleagues in the US. <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact U
FDA's Centre for Veterinary Medicine deems TriviumVet's feline HCM program eligible for expanded conditional approval pathway Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia … are excited to share results of our clinical work early next year and intend to submit our final study report to CVM once these results are available. "At TriviumVet we strive to produce treatments for clinical unmet needs and feline HCM is one of the diseases that must urgently be addressed. The interest in this treatment was highlighted in our December 2020 survey of US veterinarians carried out by Brakke Animal Health where 80% of respondents were likely to prescribe a nov … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Blog <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact Us Blog TriviumVet Secures FDA Conditional Approval for First
TriviumVet Blog - FDA deems feline HCM program eligible for expanded CA <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Con … o share results of our clinical work in client-owned cats in 2022 and intend to submit our final study report to CVM once these results are available” Hypertrophic Cardiomyopathy Cardiomyopathies are common in cats, and cardiovascular disease is one of the leading causes of mortality in this species. The most common cardiomyopathy is HCM, with an estimated prevalence of approximately 15% in the general cat population, while up to 29% of older cats may be affected. Congestive
About Us | TriviumVet <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact Us What We Do, And Why We Do it About Trivium
PBI-Gordon Companies Acquires TriviumVet, Expanding Portfolio of Innovative Treatments in Pet Health Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia Al … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
#animalhealth #veterinarymedicine #innovation #partnership #triviumvet #pbigordon #pegasuslaboratories | TriviumVet | 40 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue
Serial Entrepreneur Louise Grubb launches new podcast series <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact Us Blo … nd the scenes from one of Ireland’s most successful business sectors. The multi-award-winning serial entrepreneur Louise Grubb hosts the new series where she meets some of the key people behind Ireland’s global success in pharma, life sciences and biomedical sectors. Louise brings her twenty years of experience within the sector to the table and her own knowledge of what is required to establish a pharma success story. https://www.q1scientific.ie/q1-scientific-podcast/ Posts
#animalheartbeat #onehealth #hcm #translationalmedicine #cardiology #veterinarycardiology #feline #paediatriccardiology #emmanuelcollege #cambridge #triviumvet | Jose Novo Matos LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Re
#translationalresearch #cardiology #onehealth #veterinarymedicine #humanmedicine #felycin | Shauna O’Brien LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
TriviumVet - For our team @triviumvet ACVIM Forum is one... Facebook Log In TriviumVet's Post TriviumVet 5d · Shared with Public For our team @triviumvet ACVIM Forum is one of the highlights of our year! Scientific discovery is built on the work of teams and at ACVIM we get to meet with many of our study investigators, key opinion leaders and the best and brightest minds in veterinary medicine. This year we had two of our DVMs and clinical researchers Dr. Shauna O'Brien and Dr. Debbie Smith join us to attend talks, network and ask the big questions "What's next?"
TriviumVet Blog - Collaboration with the Dog Aging Project announcement <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Con
Irish Veterinary R&D Pioneer TriviumVet Acquired by U.S. Group PBI-Gordon in Major International Milestone; Forms Strategic Alliance with Pegasus to Launch Innovative Veterinary Drug Portfolio <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Hope for Treatment of Feline Hypertrophic Cardiomyopathy - The Cat Fanciers' Association Text ® HOME CAT TALK ECAT LOGIN CATALOG Breeds CFA Recognized Breeds View All Breeds Find a Breeder Finding the Perfect Pedigreed Kitten CFA Breed Councils Breed Councils Breed Council Secretaries Breed Council Secretary Candidates Breed Council Membership Joining a CFA Breed Council 2024 Breed Council Ballots Breed Council Resources Acceptance of New Breeds And Colors Protocol for Ballot Proposals Breed Council Website Guidelines Registration Litter and Kitten/Cat Registration Log in to eCat or M … tional Show & Expo Attending a Cat Show About Cat Shows CFA Competition Classes Award Ribbons CFA Judging Panel CFA Show Spectator Guide Show Resources Club Resources CFA Club Media Kit CFA Logo Usage CFA Show Catalog Forms CFA Show Rules Regional Show Schedulers Traditional Show Dates Judging Judging Program Judges' Code of Ethics Licensed & Associate Judges Current Judge Applicants Judges’ Emeritus Judges’ Association Spotlight Recipients Continuing Education Re … istleblower Policy Terms Of Use CFA Clubs CFA Member Clubs CFA Member Club FAQs Apply for a New Club Current Club Applicants Associated Organizations CFA Foundation EveryCat Health Top Cats Gallery View by Award Type All Award Types National Winners Top Cats Top Kittens Top Cats in Premiership Top Household Pets Breed Winners Grands Grands of Distinction View by Region All Regions Regions 1-9 China International View by Year All Years 2024-25 2023-24 2022-23 2021-22 2020-21 2 … Show Showing Household Pets Show Cages Scoring & Show FAQs Exhibitor Resources Award Point Minimums CFA Show Rules CFA Breed Standards CFA Announcements ePoints Access (via eCat) Grands & Distinguished Merits Grand Points Lookup (Herman) Point Chart Special Offers CFA News Behavior Breeds Education Health and Care Features Cat Talk Staff All Categories CFA News Behavior Breeds Education Health and Care Features Cat Talk Staff Hope for Treatment of Feline Hypertrophic Cardiom … e. “CA” stands for conditional approval. The number after CA is the application number. Drugs can apply for up to five conditional approvals while still undergoing trials for full approval. The first rapamycin drug will be felycin ® -CA1. The clinical approval of each application expires after one year. (8) What’s Next: the
| Cat Owners Talk about their participation in the RapaCat Study | Ever wonder what it is like having your pet participate in a clinical study? Check out this snippet from the acclaimed U.S television show ‘Viewpoint with Dennis Quaid’ where you will get an insight from Deidre and Jessica and their two cats George and Punky who were patients in the RapaCat clinical study, the positive results from this study have led to the development of the upcoming HALT study. For more information on HALT and to see the full video! – Visit https://hubs.ly/Q02rt-lp0 | TriviumVet
Expo Harvester - FelineVMA 2026 Exhibitor Portal Conference Details | Technical Support Technical Support Hours: 9 – 9 ET, Mon - Fri Phone: (Direct) (410) 638-9239 Email: [email protected] Web: www.ConferenceHarvester.com close this panel FelineVMA 2026 Broward County Convention Center Ft. Lauderdale, Florida Dates: September 24 – 27, 2026 (Thursday – Sunday) Website: Click here Conference Specialist Kathy LaMastra ( [email protected] ) Phone: (908) 359-9351 close this panel FelineVMA 2026 Conference Exhibitor Portal Welcome to the FelineVMA 2026 Co
VMX 2026 NAVC was an incredible milestone for TriviumVet as we saw the launch of Felycin-CA1 to the wider veterinary community and we partnered with our sister company @prnpharmacal to fight back against Feline Hypertrophic Cardiomyopathy. Felycin-CA1 scooped a Vetty award for trade show marketing, the REVERSE CKD study gained more sites and referrals and the CHASE neuropathic pain study was introduced for 2026! Our founder @louisegrubb was also recognised for her incredible contribution to veterinary health by the @featherinhercap awards. We could not complete exciting veterina
At TriviumVet we are committed to furthering and investing in the latest animal health research. We are delighted to sponsor this session focusing on Feline Hypertrophic Cardiomyopathy (HCM) at the… | Louise Grubb LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at a
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
TriviumVet - Thanks to The Currency for covering our... Facebook Log In TriviumVet's Post TriviumVet August 29, 2022 · Shared with Public Thanks to The Currency for covering our recent €6.5M fundraise. We are especially proud to have so many entrepreneurs, friends and family support us on the next stage of the TriviumVet journey! It is an exciting chapter ahead and you can read more below https://loom.ly/j7WVNXs thecurrency.news Some of Ireland’s best-known entrepreneurs and executives have backed Triviumvet. Its CEO explains why - The Currency All reactions: 12 1 comment Like Comment Mos
#felinecardiology #aafp #felinehcm | TriviumVet LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and
PBI-Gordon Companies Acquires TriviumVet, Expanding portfolio of Innovative Treatments in Pet Health - PBI-Gordon Companies Our Companies About Us News Contact Us Careers OUR NEWS Home » News » PBI-Gordon Companies Acquires TriviumVet, Expanding portfolio of Innovative Treatments in Pet Health Back PBI-Gordon Companies Acquires TriviumVet, Expanding portfolio of Innovative Treatments in Pet Health May 19, 2025 | News The strategic combination brings leading-edge product Felycin ® -CA1 (Sirolimus Delayed-Release Tablets) and innovative pipeline together with PRN ® Pharmacal leading expertise in
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Just a moment... Verifying your connection... Please wait a few seconds while we check your browser. NC State Web Publishing
 US 12,599,590 B2 Veterinary formulations comprising rapamycin and methods of using the same for treating animal disease Tom Brennan, Clonmel (IE); Louise Grubb, Tramore (IE); Liam Byrne, Waterford (IE); and Stuart Fitzgerald, Waterford (IE) Assigned to TriviumVet DAC, Waterford (IE) Appl. No. 17/777,800 Filed by TriviumVet DAC, Waterford (IE) PCT Filed Dec. 18, 2020, PCT No. PCT/IB2020/062204 § 371(c)(1), (2) Date May 18, 2022, PCT Pub. No. WO2021/124264, PCT Pub. Date Jun. 24, 2021. Claims priority of provisional application 62/950,480, filed on Dec. 19, 2019. Prior Publication
TriviumVet – Innovating with an Eye on Global Pet Healthcare | Enterprise Ireland How can we help? Search See Results I’m an Irish company I want to connect with Irish companies Search Submit a Claim Contact Us Supports Back Supports By Support Market access Capability development Funding and grants By Business Startups SMEs Large companies Researchers By Goal Expand your business Grow internationally Become more sustainable Become more innovative Become more competitive Enhance sales and marketing About Back About Who we are About Enterprise Ireland Our team Careers at Enterprise Ireland What … om Events Upcoming events Insights Insights and webinars Market Research Center Submit a Claim Contact Us Search TriviumVet – Innovating with an Eye on Global Pet Healthcare 25th April 2022 “The research and validation work we embarked on with the Innovation Voucher Scheme from Enterprise Ireland gave us a very data-driven solid foundation as a platform to be able to make sound strategic decisions and move to the next stages of our ambitions” – Dr Liam Byrne, Head of Technica … to test whether a concept is valid, the innovation voucher can be invaluable”. Submit a Claim News Insights & webinars Events Submit a Claim Insights & webinars News Events Phone +353 (1) 7272000 Head office East Point Business Park The Plaza Dublin 3 D03 E5R6 Manage Cookies support Funding and grants Market access Capability development For startups For SMEs For large companies For research organisations about Our team Careers at Enterprise Ireland Our services Succ
Dr. Liam Byrne - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Dr. Liam Byrne Head Of Technical & Business Development at TriviumVet Dr. Liam Byrne 's Executive Work History Current Head Of Technical & Business Development , Head Of Technical & Business Development Equilar on 08/15/2025 TriviumVet Past To view Dr. Liam Byrne's complete executive work history, sign up now
I’m delighted to announce that I am joining the exciting team at TriviumVet as Financial Controller. I’m really looking forward to the new opportunity and the next chapter in my career. | Lena Phelan | 56 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at a
#hypertrophiccardiomyopathy #felinehcm #hcm #ckd | TriviumVet LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy … ht back against Feline Hypertrophic Cardiomyopathy. Felycin-CA1 scooped a Vetty award for trade show marketing, the REVERSE CKD study gained more sites and referrals and the CHASE neuropathic pain study was introduced for 2026! Our founder Louise Grubb was also recognised for her incredible contribution to veterinary health by the Feather In Her Cap Awards . We could not complete exciting veterinary R&D without our network of key opinion leaders and specialists from acros … (AVMF), the AVMA’s charitable arm, has partnered with the Stanton Foundation to fund clinical research that will look into cost-effective diagnostic or treatment options for dogs that veterinarians can offer to clients with limited veterinary care budgets. Read more from AVMA News: https://bit.ly/3O0eamD AVMF, Stanton Foundation fund $150K research grant avma.org 14 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Pete Orpin FRCVS 4mo Report this
TriviumVet Receives FDA Conditional Approval for Liavium-CA1 <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact Us Blo … the pivotal effectiveness study that will form the cornerstone of the company’s application for full FDA approval of Liavium-CA1. The LUNA Study will evaluate the effectiveness of Liavium-CA1 in a well-defined canine patient population diagnosed wit h CM and SM, utilisi ng validated pain and quality-of-life outcome measures assessed by both veterinary clinicians and dog owners. The protocol is being designed to reflect the rigorous standards required by the FDA’s Center for V
I am super proud of our team at TriviumVet on the milestone of the publishing of the Felycin RapaCat Study Results. This marks a ground-breaking advancement in the fight against feline HCM and is an… | Sarah O'Connor LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choic
Meet The Team | TriviumVet <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact Us Meet The Team Who Will You Be Working … share the same passion for improving animal health. We have a talented team of award winning entrepreneurs, veterinarians, doctors and scientists and together we continue to push the boundaries of science and technology towards our collective goal. Clinical Trials Louise Grubb Managing Director Louise Grubb is a serial life science entrepreneur and inventor. She previously founded NutriScience, which develops, manufactures, and markets novel veterinary nutraceuticals,
Error Facebook Facebook is not available on this browser To continue using Facebook, get one of the browsers below. Learn more English (US) + Meta © 2026
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
PBI-Gordon Companies Acquires TriviumVet, Expanding Portfolio of Innovative Treatments in Pet Health - PRN Pharmacal Pharmaceuticals Felycin®-CA1 Firocoxib Chewable Tablets for Dogs Firocoxib Tablets for Horses KBroVet® Liavium™-CA1 PROIN ER™ PROIN® ReBalance® Antiprotozoal Oral Suspension Reconcile® Nutritional Therapeutics CitraVet® CoproBan® CranMate® Duralactin® Canine Chewable Tablets Duralactin® Canine Joint Plus Soft Chews Duralactin® Canine Soft Chews Duralactin® Equine Joint Plus Pellets Duralactin® Equine Pellets Duralactin® Feline + Fatty Acids Soft Chews Duralactin® Feline Capsules … athic Epilepsy in Dogs Galkin Honored With PRN® Pharmacal Veterinary Technician Award Hoffman Wins First PRN® Pharmacal Veterinary Technician Award PRN Pharmacal Announces Veterinary Technician Awards Program to Honor Exceptional Care Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care Categories News & Updates 850.476.9462 [email protected] Products Products Pharmaceuticals Nutritional Therapeutics Nutritional Supplements Gastrointestinal
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.4 %���� 5 0 obj > endobj xref 5 31 0000000016 00000 n 0000001120 00000 n 0000001192 00000 n 0000001516 00000 n 0000001645 00000 n 0000001767 00000 n 0000001894 00000 n 0000002823 00000 n 0000003630 00000 n 0000004520 00000 n 0000005316 00000 n 0000006195 00000 n 0000006980 00000 n 0000007797 00000 n 0000008492 00000 n 0000008528 00000 n 0000008598 00000 n 0000015020 00000 n 0000015248 00000 n 0000016023 00000 n 0000016425 00000 n 0000022714 00000 n 0000022931 00000 n 0000023138 00000 n 0000023435 00000 n 0000028746 00000 n 0000028971 00000 n 0000029588 00000 n 0000029994 00000 n 0000056 … obj > endobj 2 0 obj > endobj 3 0 obj >stream Skia/PDF m91 Google Docs Renderer application/pdf Key Facts about the DAP_2021-04-07 2021-04-09T08:44:16+01:00 2021-04-09T08:44:16+01:00 2021-04-09T08:44:16+01:00 uuid:319590de-0063-4d76-8ebb-7d2adebfc89a uuid:58835514-a9ae-4d8b-9262-e95d6d52a146 endstream endobj 4 0 obj > endobj xref 0 5 0000000000 65535 f 0000075981 00000 n 0000076030 00000 n 0000076081 00000 n 0000079445 00000 n trailer ]>> startxref 116 %%EOF
TriviumVet's Chief Scientific Officer, Dr. Stuart Fitzgerald appointed to NC State Industry Advisory Council <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint
TriviumVet - Jobs | BeBee Skip to main content Jobs People Services CV Builder Blog Connecting talent with opportunities. Jobs, services, and freelance in one place. Navigation Search jobs People Companies Services Talent Salary Guide Job Market Report Industries Job Market by City Skills Professions Job Market Trends Remote Jobs Blog Employer resources BeBee For job seekers For employers Offer your services Find a professional Bloggers About How It Works Help Center Premium Academy & AI Academy beBee CV Builder Learn anything Skill Gap Analysis Interview Prep Career Coach Legal Privacy po
TriviumVet Blog - Working with Texas A&M University on clinical trial to evaluate a new drug to treat dilated cardiomyopathy in dogs <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study … olm , an SATH cardiology resident whose work on The REPAIR Study is part of her residency research. To complete this study, the SATH is looking to enroll 12 dogs with preclinical DCM—no more than six Doberman Pinschers (the breed most commonly affected by DCM) and up to two dogs of any other breed. Eligible dogs must be older than 3 years, be on a stable dose of pimobendan (Vetmedin) for at least 60 days prior to the screening examination, have no evidence of congestive heart
TriviumVet - We're looking for a Manager of Clinical... Facebook Log In TriviumVet's Post TriviumVet April 28 · Shared with Public We're looking for a Manager of Clinical Affairs to join us for a 14-month contract At TriviumVet, we're a small R&D team with a big mission — bringing first-to-market diagnostics and therapeutics to companion animal health. If you're a senior clinical affairs professional who loves the science and the people side of the job, we'd love to hear from you. You'll be: Leading the planning, execution and compliance of preclinical an
Blog | TriviumVet (4) <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact Us Blog TriviumVet Secures FDA Conditional Ap
TriviumVet Blog - TriviumVet become sponsor of the fourth annual Feather In Her Cap Awards <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid … sponsor of the fourth annual Feather In Her Cap Awards. The Feather In Her Cap Award was created to recognize women who have made a major contribution to the animal health industry, to both reward excellence, and inspire young women in the industry. Founder and CEO Louise Grubb is passionate about championing women in the life science industry and this sponsorship is an excellent way to highlight talent and inspire the next generation of leaders. The awards take place virtua
Louise Grubb, founder and CEO of TriviumVet, was a guest speaker in the New Enterprise Development module at DCU Business School this week. In her session, Louise shared valuable insights into… | Eric Clinton LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any ti … ts from one of the industry’s top innovation leaders — and take note before you apply for the AHNTI Europe 2026 Innovation Showcase. 🚀 Apply now before this Friday, 14 November: https://lnkd.in/eRCgVesN #AHNTIEurope #AnimalHealth #AgTech #InnovationShowcase #StartupAdvice #BoehringerIngelheim #PitchToInvestors 4 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Emma Laurenson 6mo Report this post More brilliant news for Scotland's biotech sector w … managing chronic joint disease, these sessions offer critical insights you can apply in practice. And if you want to see the translational CSU research that backs it all up, make sure you stick around for Wednesday's presentations. Visit us at Booth 1343 to talk through the exciting CSU research or to dive deeper into any of the topics discussed this week. #AAEP2025 #EquineVet #JointHealth #iPAAG #VeterinaryInnovation #PerformanceHorse 16 Like Comment Share Copy LinkedIn Fac
Blog | HubSpot Author <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact Us Blog TriviumVet Secures FDA Conditional Ap
TriviumVet - Innovative Animal Health Therapeutic Solutions <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact Us Game
Blog (2) <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint With Dennis Quaid Upcoming Events Contact Us Blog TriviumVet Secures FDA Conditional Approval for Fi … to NC State’s Olby as she Wins 2023 AVMA Career Achievement in Canine Research Award 18th July Dr. Olby, is a professor of veterinary neurology and neurosurgery at the North Carolina Veterinary School, she has authored or co-authored more than 200 scientific papers, most... Read More TriviumVet Sponsor renowned ECVPT European College of Veterinary Pharmacology & Toxicology Event 10th July It was a busy week last week in TriviumVet as we were delighted to be a sponsor of … More TriviumVet CEO Louise Grubb wins IMAGE PwC Business Woman of the Year 2023 Award 17th April Serial entrepreneur Louise Grubb, founder and CEO of the game-changing companion animal diagnosis and treatment business TriviumVet, was awarded the overall title of Businesswoman... Read More TriviumVet appoint healthcare powerhouse Helen Ryan as Chairperson of their board 17th February TriviumVet™ are delighted to announce that Helen Ryan has been appointed as our new board Chai … to NC State’s Olby as she Wins 2023 AVMA Career Achievement in Canine Research Award 18th July Dr. Olby, is a professor of veterinary neurology and neurosurgery at the North Carolina Veterinary School, she has authored or co-authored more than 200 scientific papers, most... Read More TriviumVet Sponsor renowned ECVPT European College of Veterinary Pharmacology & Toxicology Event 10th July It was a busy week last week in TriviumVet as we were delighted to be a sponsor of … More TriviumVet CEO Louise Grubb wins IMAGE PwC Business Woman of the Year 2023 Award 17th April Serial entrepreneur Louise Grubb, founder and CEO of the game-changing companion animal diagnosis and treatment business TriviumVet, was awarded the overall title of Businesswoman... Read More TriviumVet appoint healthcare powerhouse Helen Ryan as Cha
TriviumVet Blog - Sponsor renowned ECVPT European College of Veterinary Pharmacology & Toxicology Event <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1"> To keep up with the latest TriviumVet product news, sign up to our newsletter here Home About Us Meet The Team Products Felycin®-CA1 Feline Chronic Kidney Disease (CKD) Canine Neuropathic Pain Proton Pump Inhibitor Clinical Trials HALT Study REVERSE Study CHASE Study The Dog Aging Project REPAIR Study RAPASAS Study News Latest News Viewpoint W